Ash Stevens to make API for Takeda's new oral blood cancer drug

By Gareth Macdonald

- Last updated on GMT

Ash Stevens to make API for Takeda's new oral blood cancer drug
The US FDA has cleared Ash Stevens to make the API for Takeda's new multiple myeloma drug Ninlaro, which is the first oral proteasome inhibitor to be approved in the country.

The US contract manufacturing organisation (CMO) will produce the active pharmaceutical ingredient (API) - ixazomib - at its facility in Riverview, Michigan.

Ninlaro – which was developed by Takeda subsidiary Millennium Pharmaceuticals – was cleared as a treatment for multiple myeloma by the US regulator last Friday. It is the first oral proteasome inhibitor to be approved in the US.

Production volumes are not being disclosed, but Ash Stevens CEO Stephen Munk told us "We anticipate that in terms of API, it will be a low volume material like other proteasome inhibitors." 

He predicted that the drug will be "a tremendous benefit for patients indicated in combination with leanlidomide and dexamethasone for the treatment of patients multiple myeloma who have received at least one prior therapy.

MM market

Ninlaro is intended as an alternative to Takeda's market-leading treatment Velcade (bortezomib), which is due to lose patent protection in the US in 2017.

Ash Stevens also makes the API for Velcade as Munk explained.

"We were the first FDA approved supplier of bortezomib, the API in Velcade and we continue to supply that API to Takeda today" ​he said, adding that "the initial approval was in May of 2003." 

Ninlaro is the third multiple myeloma drug approved in the US this year, behind Novartis’s Farydak (panobinostat) and Johnson & Johnson’s Darzalex (daratumumab).

Related news

Show more

Related products

show more

Increasing the Bioavailability of Oncology Drugs

Increasing the Bioavailability of Oncology Drugs

Content provided by Lonza Small Molecules | 13-Nov-2023 | White Paper

Oral tyrosine kinase inhibitors (TKIs) are a class of cancer drugs that can be highly susceptible to issues with solubility in the gastrointestinal tract

Efficient Freezing & Storage of Biopharmaceuticals

Efficient Freezing & Storage of Biopharmaceuticals

Content provided by Single Use Support | 06-Nov-2023 | White Paper

Various options exist for freezing biopharmaceutical bulk material, but selecting the most effective and efficient approach for each cold chain can be...

Manufacturing Drugs with Highly Potent APIs

Manufacturing Drugs with Highly Potent APIs

Content provided by Altasciences | 28-Sep-2023 | White Paper

In this issue of The Altascientist, we examine the critical considerations for the safe and compliant manufacture of drugs with highly potent APIs (HPAPIs),...

Follow us

Products

View more

Webinars